Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Abstract

SummaryBackgroundStatin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.MethodsIn this meta-analysis, randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger, 56–60 years, 61–65 years, 66–70 years, 71–75 years, and older than 75 years). We estimated effects on major vascular events (ie, major coronary events, strokes, and coronary revascularisations), cause-specific mortality, and cancer incidence as the rate ratio (RR) per 1·0 mmol/L reduction in LDL cholesterol. We compared proportional risk reductions in different age subgroups by use of standard χ2 tests for heterogeneity when there were two groups, or trend when there were more than two groups.Findings14 483 (8%) of 186 854 participants in the 28 trials were older than 75 years at randomisation, and the median follow-up duration was 4·9 years. Overall, statin therapy or a more intensive statin regimen produced a 21% (RR 0·79, 95% CI 0·77–0·81) proportional reduction in major vascular events per 1·0 mmol/L reduction in LDL cholesterol. We observed a significant reduction in major vascular events in all age groups. Although proportional reductions in major vascular events diminished slightly with age, this trend was not statistically significant (ptrend=0·06). Overall, statin or more intensive therapy yielded a 24% (RR 0·76, 95% CI 0·73–0·79) proportional reduction in major coronary events per 1·0 mmol/L reduction in LDL cholesterol, and with increasing age, we observed a trend towards smaller proportional risk reductions in major coronary events (ptrend=0·009). We observed a 25% (RR 0·75, 95% CI 0·73–0·78) proportional reduction in the risk of coronary revascularisation procedures with statin therapy or a more intensive statin regimen per 1·0 mmol/L lower LDL cholesterol, which did not differ significantly across age groups (ptrend=0·6). Similarly, the proportional reductions in stroke of any type (RR 0·84, 95% CI 0·80–0·89) did not differ significantly across age groups (ptrend=0·7). After exclusion of four trials which enrolled only patients with heart failure or undergoing renal dialysis (among whom statin therapy has not been shown to be effective), the trend to smaller proportional risk reductions with increasing age persisted for major coronary events (ptrend=0·01), and remained non-significant for major vascular events (ptrend=0·3). The proportional reduction in m...

Statins in Older Danes: Factors Associated With Discontinuation Over the First 4 Years of Use

“…Older persons, and particularly those older than 80 years, are poorly represented in most clinical trials of statins . Despite a recent meta‐analysis in persons older than 75 years, the efficacy and safety of statins in this age group are still largely unclear, particularly for primary prevention and among those who are frail or have multiple comorbidities . Consequently, there are questions as to whether statins could and should be initiated in this population, and whether discontinuation can or should be considered in existing users .…”

The Association Between Low‐Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts

“…Rather, our findings indicate those at high risk for CVD based on non–lipid‐related risk factors, such as hypertension, diabetes, and smoking, should be targeted for lipid‐lowering therapy regardless of starting LDL‐C levels. The effectiveness of statin therapy to lower CVD risk is supported by a wealth of evidence demonstrating the benefit of LDL‐C lowering with statin and nonstatin lipid‐lowering therapies, with no lower LDL‐C limit for ASCVD risk reduction, and a benefit proportional to absolute risk and LDL‐C reduction . Yet, to date, there are limited clinical trial data evaluating the effectiveness of lipid‐lowering therapy in older adults without established ASCVD .…”

Could giving statins to over 75s really save 8000 lives a year?

“…Similarly, it found no statistically significant benefits in reducing major vascular events among over 75s (fig 3 in the paper) 1. How, then, did the authors justify concluding that “statin therapy produces significant reductions in major vascular events irrespective of age”?…”

“…Yet the meta-analysis from the Cholesterol Treatment Trialists’ Collaboration, published in the Lancet in February, did not mention this claim—or seem to warrant these headlines 1. It showed that over 75s who took statins and had no history of heart problems were no more likely to survive over the next five years than people not taking them.…”